Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.10M$2.10Mderived+167.3% vs Q4 2021 Net Income-$1.41M-$1.41MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$961,000+200.3% Operating Incomederived-$1,416,000N/M Operating Cash Flowderived$41,000N/M Margins · derivedGross margin45.8%+5.0 pt vs Q4 2021
Operating margin-67.6%+157.3 pt vs Q4 2021
Net margin-67.2%+161.3 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end